Calithera Biosciences (CALA) Prices 5M Share Common Offering at $6.25/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
After-Hours Stock Movers 04/15: (RCUS) (AM) (BBBY) Higher; (ATHX) (CALA) (LAKE) Lower (more...)
April 15, 2020 6:03 PM EDTToday's After-Hours Stock Movers
Arcus Biosciences (NYSE: RCUS) 47.5% HIGHER; Gilead (NASDAQ: GILD) is considering acquiring a stake in Arcus Biosciences (NYSE: RCUS), according to Bloomberg, citing people familiar with the matter.
Antero Midstream (NYSE: AM) 16.8% HIGHER; said first quarter 2020 dividend is unchanged as compared to the fourth quarter of 2019.
Bed Bath & Beyond (NASDAQ: BBBY) 14.4% HIGHER; reported Q4 EPS... More
Calithera Biosciences (CALA) Commences Underwritten Public Offering of Common
April 15, 2020 4:02 PM EDTCalithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that it intends to offer and sell shares of its common stock in an... More
Calithera Biosciences (CALA) Provides Update on Business Operations
April 14, 2020 7:05 AM EDTCalithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small-molecule drugs for the treatment of cancer and other life-threatening diseases, shared an update on business operations, including clinical program adjustments related to COVID-19.
Our first priority during the COVID-19 pandemic is the health of our employees, as well as patients and medical professionals involved in our clinical programs. We are continuing all clinical operations, with additional COVID-19 related safety measures in place. Given the fluid nature of the current situation, and the impact of the... More
